Prevention of benign paroxysmal positional vertigo with vitamin D supplementation

Jeong, Seong Hae; Kim, Ji Soo; Kim, Hyo Jung; Choi, Jeong Yoon; Koo, Ja Won; Choi, Kyeongdal; Park, Ji Yun; Lee, Seung-Han; Choi, Seo Young; Oh, Sun Young; Yang, Tae Ho; Park, Jae‐Han; Jung, Inhwa; Ahn, Soyeon; Kim, Soo-Yeon

doi:10.1212/wnl.0000000000010343

Cited by 58 publications

(57 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On these bases, vitamin D supplementation has been suggested to decrease recurrent attacks of BPPV. Interestingly, some recent prospective, randomized, and controlled trials have indicated a preventive effect of vitamin D supplementation on the occurrence rate of BPPV [59]. Based on this evidence vitamin D supplementation may be considered in patients with frequent relapses of BPPV and reduced vitamin D serum levels.…”

Section: Benign Paroxysmal Positional Vertigo (Bppv)mentioning

confidence: 99%

Current Insights into Treating Vertigo in Older Adults

Casani¹,

Gufoni²,

Capobianco³

2021

Drugs Aging

View full text Add to dashboard Cite

The number of older people has been increasing over recent decades in Western populations. Dizziness, imbalance, and vertigo constitute some of the most common complaints in older patients, and risk of falling is the most frequent and worrying consequence. It has been reported that 15-20% of the adult population experiences these debilitating symptoms. Among the diseases that may be associated with vertigo, the three classes of otological, central, and functional (psychological) dizziness may be distinguished. Overall, vestibular disorders account for 48% of vertiginous complaints in the older population. The main focus of this article is to review the forms of pharmacotherapy for vertigo, especially with regard to older patients, who may be treated simultaneously with other drugs for different comorbidities. Interactions with other drugs should be considered in the choice of a particular course of treatment. Moreover, overuse of pharmacotherapy for the management of vertigo in the elderly may prevent the development of the central compensatory mechanism that sustains both static and dynamic imbalance after a vertiginous crisis. In the majority of patients, vestibular and physical rehabilitation are strongly advised and rarely contraindicated.

show abstract

Section: Benign Paroxysmal Positional Vertigo (Bppv)mentioning

confidence: 99%

Current Insights into Treating Vertigo in Older Adults

Casani¹,

Gufoni²,

Capobianco³

2021

Drugs Aging

View full text Add to dashboard Cite

show abstract

“…A significant reduction in the recurrences was found in the treatment group (Fig. 1a) [73]. A subsequent meta-analysis of six randomized trials also proved the preventive effect of vitamin D supplementation on recurrences of BPPV ( Fig.…”

Section: Treatmentsmentioning

confidence: 66%

Update on benign paroxysmal positional vertigo

2020

Self Cite

View full text Add to dashboard Cite

Benign paroxysmal positional vertigo (BPPV) is the most common cause of vertigo worldwide. This review considers recent advances in the diagnosis and management of BPPV including the use of web-based technology and artificial intelligence as well as the evidence supporting the use of vitamin D supplements for patients with BPPV and subnormal serum vitamin D. Keywords Dizziness • Vertigo • Benign paroxysmal positional vertigo Hyo-Jung Kim and JaeHan Park equally contributed to this study.

show abstract

“…As prevention of recurrence of BPPV, and with limited rationale, in preventing severe forms of COVID-19, vitamin D3 is used to a greater extent worldwide, due to its low level in the general population, and also very small side effects [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Post-COVID-19 Benign Paroxysmal Positional Vertigo

Maslovara

2021

Case Reports in Medicine

View full text Add to dashboard Cite

Background. COVID-19 is a disease caused by a new strain of coronavirus (SARS-COVID-19). The WHO first learned about this new virus on December 31, 2019, following a report on a group of cases of “viral pneumonia” in Wuhan, People’s Republic of China, and declared a pandemic in March 2020. The disease was an almost complete unknown at the outset, but knowledge of its pathophysiology, clinical picture, and treatment options grew and developed rapidly. Objective. Dizziness is a very common symptom that patients report in routine clinical practice and one of the significant clinical manifestations of COVID-19. This short report investigated a possible connection between COVID-19 and benign paroxysmal positional vertigo (BPPV). Methods. We present two cases of benign paroxysmal positional vertigo (BPPV), which developed within two weeks of SARS-COVID-19 infection, manifesting with mild disease severity in early November 2020. Results. In both cases, the disease manifested by severe, short-lived attacks of vertigo, objective-circular type, with accompanying nausea and vomiting. The symptoms occurred when lying in bed and turning to the right and assuming an upright position. The diagnosis of posterior semicircular canal BPPV (PC-BPPV) was made based on a subjectively and objectively positive right-sided Dix–Hallpike test. Conclusions. The pathophysiology of post-COVID BPPV is probably similar to that of other viral infections, with some of its specificities such as inducing hypercoagulation and microthrombus formation, which can cause significant circulatory disorders possibly affecting its pathogenesis.

show abstract

Prevention of benign paroxysmal positional vertigo with vitamin D supplementation

Cited by 58 publications

References 35 publications

Current Insights into Treating Vertigo in Older Adults

Current Insights into Treating Vertigo in Older Adults

Update on benign paroxysmal positional vertigo

Post-COVID-19 Benign Paroxysmal Positional Vertigo

Contact Info

Product

Resources

About